» Articles » PMID: 6378228

Transient Renal Dysfunction During Initial Inhibition of Converting Enzyme in Congestive Heart Failure

Overview
Journal Br Heart J
Date 1984 Jul 1
PMID 6378228
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment with captopril in resistant normotensive congestive heart failure is associated with a pronounced reduction in blood pressure, particularly after the first dose. The effects of this reduction on renal function were assessed in 10 patients at the beginning of and during chronic treatment (at one week and three months). Renal plasma flow and glomerular filtration rates were measured by isotope clearance during water diuresis. The first dose of captopril (25 mg) led to a pronounced fall in renal plasma flow and glomerular filtration rates together with a decrease in mean arterial pressure; this fall correlated with baseline plasma renin activity. These changes were paralleled by decreases in water and sodium excretion. In contrast, by the end of the first week of treatment a similar fall in mean arterial pressure occurred together with a pronounced increase in renal plasma flow; the glomerular filtration rate was maintained and there was no decrease in water and sodium excretion. This new response pattern recurred after three months of treatment. The difference in response at different stages of treatment may reflect the balance between the different mechanisms influencing kidney dynamics in heart failure and their alteration by converting enzyme inhibition. The sustained increase in renal plasma flow during chronic treatment with captopril may account for the continued control of heart failure in these patients.

Citing Articles

Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure.

Murray L, Squire I, Reid J, Lees K Br J Clin Pharmacol. 1998; 45(6):559-66.

PMID: 9663811 PMC: 1873653. DOI: 10.1046/j.1365-2125.1998.00728.x.


Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Brogden R, Todd P, Sorkin E Drugs. 1988; 36(5):540-600.

PMID: 3063499 DOI: 10.2165/00003495-198836050-00003.


Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

DiBianco R Med Toxicol. 1986; 1(2):122-41.

PMID: 3023783 DOI: 10.1007/BF03259832.


Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.

Funck-Brentano C, Chatellier G, Alexandre J Br Heart J. 1986; 55(6):596-8.

PMID: 3013264 PMC: 1236768. DOI: 10.1136/hrt.55.6.596.


Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Cleland J, Dargie H, Ball S, Gillen G, Hodsman G, Morton J Br Heart J. 1985; 54(3):305-12.

PMID: 2994698 PMC: 481900. DOI: 10.1136/hrt.54.3.305.


References
1.
Strauss H, Pitt B . Evaluation of cardiac function and structure with radioactive tracer techniques. Circulation. 1978; 57(4):645-54. DOI: 10.1161/01.cir.57.4.645. View

2.
Curtis J, Luke R, Whelchel J, Diethelm A, Jones P, DUSTAN H . Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983; 308(7):377-81. DOI: 10.1056/NEJM198302173080707. View

3.
Bravo E, TARAZI R, DUSTAN H . On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med. 1974; 83(1):119-28. View

4.
Levens N, Peach M, Carey R . Role of the intrarenal renin-angiotensin system in the control of renal function. Circ Res. 1981; 48(2):157-67. DOI: 10.1161/01.res.48.2.157. View

5.
Gould L, Reddy C . Phentolamine. Am Heart J. 1976; 92(3):397-402. DOI: 10.1016/s0002-8703(76)80121-4. View